PNT2001 is a next-generation PSMA radioligand that has unique linker technology that enables increased tumor accumulation, potentially enabling lower doses of radioisotope to reduce off target toxicity while allowing for the same level of tumor kill.

Licensed from Scintomics GmbH, the intent of the PNT2001 program is to advance the lead drug candidate into clinical development in the nmCSPC space. In preclinical studies, the PNT2001 compounds have demonstrated increased tumor accumulation compared to PNT2002 and have greater cell internalization. We expect the selected compound will be paired with either an alpha or beta emitter and may be positioned for use in earlier-stage cancer treatment.